Producer prices rose 0.5% last month, exceeding forecasts and marking the quickest pace in three months, as a sharp jump in services costs offset stable goods prices, signaling persistent inflationary pressures in the pipeline.
With U.S. natural gas futures soaring ahead of a major winter storm, investor focus turns to producers like Comstock Resources. The stock's recent rally contrasts with a complex valuation picture, raising questions about its true worth in a volatile energy market.
Shares of Meta Platforms soared Thursday, fueled by a significant price target upgrade from BofA Securities. The rally comes despite the company reporting a slight dip in full-year profit, as investors focus on strong revenue growth and the company's positioning in the artificial intelligence race.
In its Q4 2025 earnings call, CNX Resources outlined a disciplined capital strategy for 2026, emphasizing operational resilience amid severe weather and providing updates on its deep Utica shale program, RNG initiatives, and hedging posture. Management signaled a focus on long-term infrastructure catalysts rather than chasing volatile spot gas prices.
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Goldman Sachs raises Sweetgreen's price target to $5.60, citing policy tailwinds for consumer spending, even as it maintains a Sell rating. The salad chain's expansion and strong revenue growth continue to draw investor attention.
Piper Sandler raises its price target on Kura Sushi USA (KRUS) following an investor meeting, citing potential from recent changes to its digital loyalty platform. The company also appointed a new marketing-focused director as it eyes U.S. expansion.
Lake Street Capital maintains a Buy rating on The ONE Group Hospitality (STKS) despite lowering its price target, citing a solid finish in a tough market and a clear growth runway through 2026.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
TD Cowen reaffirms its Buy rating on Dynatrace (DT) while adjusting its price target, anticipating stronger-than-expected performance driven by its new AI-powered observability platform, Dynatrace Intelligence.
Despite a 14% share price decline over the past quarter, Associated British Foods (LON:ABF) demonstrates robust underlying financial health, driven by strong earnings growth and efficient capital reinvestment, suggesting potential for a market correction.
ABB's shares surged 10% following its annual results, with earnings per share exceeding forecasts. Analysts have raised their price target to CHF 60.30 and project accelerated revenue growth ahead of industry peers.
Despite a robust 57% return over three years, a deep dive into Warby Parker's financials reveals a significant disconnect between its current share price and intrinsic value estimates, raising questions about its growth trajectory justifying the premium.
A revised analyst price target for Grupo Financiero Banorte (BMV:GFNORTE O) is refocusing investor attention on the Mexican banking giant, highlighting how evolving assessments of risk and growth potential can rapidly reshape a stock's narrative.
Insurance brokerage giant Brown & Brown sees a key price target cut to $81 following its fourth-quarter earnings, which revealed robust fee growth but concerns over slowing organic revenue expansion.
Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
Truist Securities raises its price target on Huntington Bancshares (HBAN) following a robust Q4 performance, as the regional bank forecasts record interest income growth and benefits from improving industry tailwinds.
Insurance brokerage giant Arthur J. Gallagher reported robust fourth-quarter profit growth, driven by resilient demand. However, Truist Securities has lowered its price target on the stock, citing valuation pressures across the property & casualty brokerage sector.
